FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Adamas Pharmaceuticals Files NDA for Parkinsons Therapy

[ Price : $8.95]

Adamas Pharmaceuticals files an NDA for ADS-5102 (amantadine hydrochloride) extended-release capsules, indicated for treating levo...

FDA Clears SeaSpines Anterior Cervical System

[ Price : $8.95]

FDA clears a SeaSpine Holdings 510(k) for its Shoreline ACS Anterior Cervical Standalone System, which features TruProfile technol...

Salix Wants Restrictions on Xifaxan ANDAs

[ Price : $8.95]

Salix asks FDA to require several specific test results for any ANDA citing any strength or indication of Xifaxan as the reference...

GDUFA Regulatory Science Priorities

[ Price : $8.95]

FDA publishes generic drug regulatory science priorities for FY 2017.

FDA Awards Engility $112 Million Computational Science Contract

[ Price : $8.95]

FDA awards Engility Holdings a $112 million five-year contract for computational science and bioinformatics services.

SynCardia Driver System Problems Continue: FDA

[ Price : $8.95]

FDA says that new data indicate continuing increased mortality and neurological risks with use of SynCardias Temporary Total Artif...

Bio-IND MAPP Out

[ Price : $8.95]

The CDER Office of Generic Drugs issues a MAPP with policies and procedures for review of Bio-INDs.

Concerns Voiced on IRB Guidance

[ Price : $8.95]

Two stakeholders suggest improvements to an FDA/HHS guidance on written procedures for institutional review boards.

Changes Sought in 2 Compounding Guidances

[ Price : $8.95]

Four stakeholders raise concerns about and recommend changes to two draft guidances on drug compounding.

ISPE Wants Data Integrity Guidance Clarified

[ Price : $8.95]

The International Society for Pharmaceutical Engineering asks FDA for additional clarifications to a draft guidance on data integr...